Results 131 to 140 of about 35,569 (305)

Appetite Suppression by GLP‐1 Receptor Agonists: Role of Delayed Gastric Emptying

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). Methods We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity.
Mark I. Friedman, W. Scott Harmsen, Michael Camilleri   +2 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
AbstractGlucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of the GLP‐1RA class of medications has been derived from kidney‐related outcomes reported ...
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
openaire   +3 more sources

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans

Molecular Metabolism
Single molecules that combine complementary modes of action with glucagon-like peptide-1 receptor (GLP-1R) agonism are best-in-class therapeutics for obesity treatment.
Brian Finan, Jonathan D. Douros, Ronald Goldwater, Ann Maria Kruse Hansen, Julie B. Hjerpsted, Karina Rahr Hjøllund, Martin K. Kankam, Patrick J. Knerr, Anish Konkar, Stephanie A. Mowery, Timo D. Müller, John Rømer Nielsen, Sune Boris Nygård, Diego Perez-Tilve, Kirsten Raun, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi   +17 more
doaj   +1 more source

Gastrointestinal motor function and glycaemic control in diabetes.

, 2010
This thesis focuses on the role of gastric emptying and gastrointestinal hormones in the regulation of glycaemia and appetite in health and patients with type 2 diabetes.
Ma, Jing
core  

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle

, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
McKenney, Mikaela L., Bell, Lauren N., Chalasani, Naga, Schultz, Kyle A., Fullenkamp, Allison M., Sturek, Michael, Dineen, Stacey L., Alloosh, Mouhamad   +7 more
core   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in orthopaedics

SICOT-J
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery. There is growing amount of evidence of their ability to modulate the activity of osteoblasts and osteoclasts, affect inflammatory
Mavrogenis, Andreas, Altsitzioglou, Pavlos, Pililis, Sotirios, Anastasilakis, Athanasios, Tournis, Symeon, Makras, Polyzois, Saranteas, Theodosis, Lustig, Sebastien   +7 more
openaire   +2 more sources

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source